Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun;38(5):1729-1736.
doi: 10.1007/s11011-022-01131-0. Epub 2022 Nov 29.

Prevention of post-tips hepatic encephalopathy: The search of the ideal candidate

Silvia Nardelli  1 , Daniele Bellafante  2 , Lorenzo Ridola  2 , Jessica Faccioli  2 , Oliviero Riggio  2 , Stefania Gioia  2
Affiliations
Review

Prevention of post-tips hepatic encephalopathy: The search of the ideal candidate

Silvia Nardelli et al. Metab Brain Dis. 2023 Jun.

Abstract

Transjugular intrahepatic portosystemic shunt (TIPS) has been used since more than 25 years to treat some of the complications of portal hypertension, especially variceal bleeding and ascites refractory to conventional therapy. TIPS establishes a communication between the portal and hepatic veins, inducing the blood to shift from the splanchnic circulation into the systemic vascular bed with the aim of decompressing the portal venous system, and avoids the major complications of portal hypertension. However, the shunt of the portal blood into the systemic circulation is the cause of one of the major complications of the procedure: the post-TIPS hepatic encephalopathy (HE). To date, few pharmacological treatment has been proven effective to prevent this complication and thus, the identification of patients at high risk of post-TIPS hepatic encephalopathy and the patients' carefully selection is the only way to prevent this frequent complication.

Keywords: Hepatic encephalopathy; Liver cirrhosis; Myosteatosis; Portosystemic shunts; Sarcopenia; Transjugular intrahepatic portosystemic shunt.

PubMed Disclaimer

References

    1. Adlakha N, Russo MW (2020) Outcomes After Transjugular Intrahepatic Portosystemic Shunt in Cirrhotic Patients 70 Years and Older. J Clin Med 9. https://doi.org/10.3390/jcm9020381
    1. Bai M, Qi X, Yang Z, Yin Z, Nie Y, Yuan S, Wu K, Han G, Fan D (2011) Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review. J Gastroenterol Hepatol 26(6):943–951. https://doi.org/10.1111/j.1440-1746.2011.06663.x - DOI - PubMed
    1. Bass NM, Mullen KD, Sanyal A et al (2010) Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362:1071–1081 - DOI - PubMed
    1. Berlioux P, Robic MA, Poirson H, Métivier S, Otal P, Barret C, Lopez F, Péron JM, Vinel JP, Bureau C (2014) Pre-transjugular intrahepatic portosystemic shunts (TIPS) prediction of post-TIPS overt hepatic encephalopathy: the critical flicker frequency is more accurate than psychometric tests. Hepatology 59(2):622–629. https://doi.org/10.1002/hep.26684 - DOI - PubMed
    1. Bhanji RA, Moctezuma-Velazquez C, Duarte-Rojo A, Ebadi M, Ghosh S, Rose C, Montano-Loza AJ (2018) Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis. Hepatol Int 12(4):377–386. https://doi.org/10.1007/s12072-018-9875-9 - DOI - PubMed

MeSH terms

LinkOut - more resources